Drug
Pralsetinib clinical trials
Also written GAVRETO™ and BLU-667.
- studies test it
- 12
- open now
- 6
- in phase 3
- 2
- first study started
- 2017
Keep track of what changes. Save the pralsetinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 2020 (3)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2020 | 3 |
| 2021 | 3 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 7
- Phase 3
- 2
- Phase 4
- 2
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 7 · Other 5
Hoffmann-La Roche (4) · Genentech, Inc. (2) · Fondazione per la Medicina Personalizzata (1) · Fudan University (1) · Fujian Medical University (1) · Rigel Pharmaceuticals (1) · Sun Yat-sen University (1) · West China Hospital (1)
Often tested with
Tested in the same studies.
Entrectinib (5) · Alectinib (4) · Atezolizumab (4) · Ipatasertib (3) · Ado-Trastuzumab Emtansine (3) · Larotrectinib (3) · Inavolisib (2) · Divarasib (2)
Studies
Open first, then newest update. How each study uses pralsetinib is read from its arms, and is right about nine times in ten.
Testing it · 12
- A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)RecruitingPhase 2Genentech, Inc.NCT04302025Written as Pralsetinib
- Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid TumorsRecruitingPhase 4Rigel PharmaceuticalsNCT07704658Written as Pralsetinib
- Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.RecruitingPhase 2Sun Yat-sen UniversityNCT06563999Written as Pralsetinib
- A Real-world Study of Pralsetinib Combined With Leucogen in the Treatment of RET Fusion-positive NSCLCNot yet recruitingNot applicableFudan UniversityNCT07418879Written as Pralsetinib
- Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort StudyNot yet recruitingPhase 4Fujian Medical UniversityNCT07010393Written as Pralsetinib
- Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid CancerRecruitingPhase 2West China HospitalNCT06482086Written as Pralsetinib
- Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform StudyActive, not recruitingPhase 2Hoffmann-La RocheNCT04589845Written as Pralsetinib
- A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)TerminatedPhase 3Hoffmann-La RocheNCT04222972Written as Pralsetinib
- Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid TumorsCompletedPhase 1/2Hoffmann-La RocheNCT03037385Written as pralsetinib (BLU-667)
- A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of ResponseCompletedPhase 2Genentech, Inc.NCT04632992Written as Pralsetinib
- A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).WithdrawnPhase 3Hoffmann-La RocheNCT04760288Written as Pralsetinib
- The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and ImmunotherapyActive, not recruitingPhase 2Fondazione per la Medicina PersonalizzataNCT04591431Written as Pralsetinib
Codes
What other systems call pralsetinib · ClinicalTrials.gg INT001228
- MeSH (NLM) C000655704pralsetinibOne source ClinicalTrials.gov
- UNII (FDA) 1WPE73O1WVPRALSETINIBConfirmed FDA, Wikidata
- RxNorm 2394936One source FDA
- Wikidata Q97732199pralsetinibConfirmed FDA, Wikidata
- NCI Thesaurus C132295PralsetinibOne source FDA
- DrugBank DB15822One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000655704 | pralsetinib | One source ClinicalTrials.gov |
| UNII (FDA) | 1WPE73O1WV | PRALSETINIB | Confirmed FDA, Wikidata |
| RxNorm | 2394936 | — | One source FDA |
| Wikidata | Q97732199 | pralsetinib | Confirmed FDA, Wikidata |
| NCI Thesaurus | C132295 | Pralsetinib | One source FDA |
| DrugBank | DB15822 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.